Compare Citius Pharmaceuticals Inc (CTXR) vs Invesco S&P 500 Momentum ETF (SPMO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Invesco S&P 500 Momentum ETF — how do they compare? Citius Pharmaceuticals Inc trades at $0.73 (market cap $18.73M), while Invesco S&P 500 Momentum ETF trades at $149.33. The key difference: Invesco S&P 500 Momentum ETF is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | SPMO | |
|---|---|---|
Market Cap | $18.73M | — |
Sector | Health | Broad Market / Factor |
52-Week High | $1.82 | $161.66 |
52-Week Low | $0.48 | $107.84 |
Enterprise Value | $14.95M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR is trading at $0.68, up 6.28% today, with a bullish technical signal from moving averages. The company shows strong commercial momentum with LYMPHIR cancer treatment revenue reaching $5.6 million in H1 2026, though it remains unprofitable with a -823% net margin. Analyst consensus is strongly bullish with 83% buy ratings.
The outlook depends on LYMPHIR's commercial success offsetting deep losses. Near-term catalysts include expanded market access and combination therapy data, but high cash burn and execution risks require monitoring. The stock offers speculative growth potential in oncology but carries significant financial risk.
SPMO (Invesco S&P 500 Momentum ETF) trades at $149.69, up 0.4% with strong bullish momentum indicators. The ETF has demonstrated exceptional 2026 performance with 26% returns, significantly outperforming the S&P 500 while maintaining lower drawdowns. Technical analysis shows bullish moving averages but neutral oscillators, with RSI_6 at 88.22 suggesting potential overbought conditions. Recent institutional interest includes Alpha Zero LLC increasing its position by 6.4% to $10.73 million in Q1 2026.
The outlook remains positive given SPMO's momentum-driven strategy and concentrated tech exposure (55% weighting), particularly benefiting from AI-driven growth. However, risks include higher volatility during sector rotations and downside vulnerability if momentum factors reverse. The ETF's 0.13% expense ratio provides cost efficiency for momentum exposure, but investors should monitor concentration risks in technology holdings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Invesco S&P 500 Momentum ETF
SPMO is designed to track the investment results of the S&P 500 Momentum Index. This index measures the performance of stocks in the S&P 500 that exhibit the highest momentum, or the greatest price appreciation, over the trailing 12 months, while excluding the most recent month. By investing in these high-momentum stocks, SPMO seeks to capitalize on the historical trend that stocks with strong recent performance tend to continue that performance in the near term, offering a systematic approach to factor investing within the large-cap U.S. equity market.
Read more on SPMO →
